Stock Events

Stock Events

Search...

Acadia Pharmaceuticals

$19.14

81

+$0.59+3.18% Friday 20:00

Statistics

Day High

19.21

Day Low

18.55

52W High

32.59

52W Low

14.55

Volume

2,358,454

Avg. Volume

1,783,215

Mkt Cap

3.16B

P/E Ratio

-1,840.38

Dividend Yield

-

Dividend

-

Earnings

8MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-0.45

-0.2

0.04

0.29

Expected EPS

0.05

Actual EPS

0.1

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACAD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Johnson & Johnson

Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops drugs that directly compete in the neurological and psychiatric drug markets.

Eli Lilly and Company offers a range of products that target the central nervous system, making it a direct competitor in the psychiatric and neurological drug markets.

Novartis AG has a strong portfolio in neuroscience, competing in the development and marketing of drugs for psychiatric and neurological disorders.

Pfizer Inc. has a diversified portfolio that includes treatments for neurological conditions, directly competing with Acadia's offerings.

Biogen Inc. focuses on neurology, developing treatments for diseases like multiple sclerosis and Alzheimer's, areas that overlap with Acadia's focus.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries Limited has a broad portfolio that includes CNS (central nervous system) drugs, making it a competitor in the neurological and psychiatric medication market.

AbbVie Inc. has a growing interest in neuroscience, including R&D in Parkinson's and Alzheimer's, which competes with Acadia's focus areas.

Merck & Co., Inc. is involved in the development of drugs that target neurological disorders, positioning it as a competitor in the same therapeutic area as Acadia.

Sage Therapeutics

Sage Therapeutics, Inc. specializes in CNS disorders, with a focus on developing novel medicines to treat conditions that overlap with Acadia's target markets.

Alkermes plc has a focus on central nervous system (CNS) disorders, including schizophrenia and depression, directly competing with some of Acadia's key products.

Analyst Ratings

28$Average Price Target

The highest estimate is $39.

From 15 ratings within the last 6 months. This is not an investment recommendation.

Buy

73%

Hold

27%

Sell

0%

About

Health Technology

Biotechnology

Manufacturing

Pharmaceutical Preparation Manufacturing

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Show more...

CEO

Stephen Davis

Employees

610

Country

US

ISIN

US0042251084

WKN

000603035

Listings